A Novel CCM2 Gene Mutation Associated With Cerebral Cavernous Malformation

Lipeng Yang, Jian Wu* and Jing Zhang*

Department of Neurology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China

Cerebral cavernous malformations (CCMs) are the second most prevalent type of vascular malformation within the central nervous system. CCMs occur in two forms—sporadic and familial—the latter of which has an autosomal dominant mode of inheritance with incomplete penetrance and variable clinical expressivity. There are three genes considered to be associated with CCMs,—CCM1, which codes for Krit1 protein; CCM2, which codes for MGC4607 protein; and CCM3, which codes for PDCD10 protein. To date, more than 74 gene mutations of CCM2 have been reported, and ∼45% are deletion mutations. In this article, we disclose a novel CCM2 genetic variant (c.755delC, p.S252fs*40X) identified in a Chinese family to enrich the database of CCM2 genotypes.

Keywords: cerebral cavernous malformation, gene mutation, CCM2, novel mutation, susceptibility-weighted imaging (SWI)

INTRODUCTION

Cerebral cavernous malformations (CCMs) are the second most prevalent type of vascular malformation in the central nervous system (1). Histologically, the absence of pericytes and the deficiency of the tight and adherens junctions results in a single layer of endothelial cells, which leads to the impairment of the blood-brain barrier (BBB) (2). The incidence of CCM is estimated to be ∼0.1–0.5% worldwide, but the data are underestimated because ∼40% of patients are asymptomatic (3). CCMs can onset at any age but mostly occur between 20 and 50 years old (3, 4). The main clinical manifestations are intracerebral hemorrhage (ICH) and seizures, and other symptoms include recurrent headaches, focal neurological deficits, vertigo, and paresis (5, 6). MRI can be performed to diagnose CCMs. T2-weighted images can reveal the mulberry- or popcorn-like appearance and a dark rim due to hemosiderin deposition after repeated bleedings as the characteristics of CCMs. Furthermore, T2-weighted gradient echo sequences, which have more sensitivity to CMBs than T2-weighted images, can detect the small cerebral cavernomas (2, 7).

CCMs occur in two forms, a sporadic form and a familial form; the latter has an autosomal dominant mode of inheritance with incomplete penetrance and variable clinical expressivity. The proportion of familial cases was estimated as 50% in Hispanic-American patients (8). Compared to sporadic cases, familial cases are inclined to have multiple lesions (9). To date, there are three genes considered to be associated with CCMs, CCM1 (KRT11, 7q11.2-q21), CCM2 (MGC4607, 7q15-p13) and CCM3 (PDCD10, 3q25.2-q27) (10, 11), which encode the proteins krev/rap1 interacting trapped 1 (Krit1), malcavernin,
and programmed cell death 10 (PDCD10), respectively (10, 11). The three proteins constitute a heterotrimeric complex that plays an important role in endothelial cells and interacts with other signaling proteins (12).

Craig et al. (10) found that the mutation frequencies of the CCM1, CCM2, and CCM3 genes were 40, 20, and 40%, respectively, in 20 pedigrees of CCMs, and the penetrances were 88, 100, and 63% (13), respectively. Among these three genes, CCM2 used to be the only one with 100% of clinical and radiological penetrance (13). In 2018, however, Scimone et al. (14) found that penetrance of CCM2 was only 70% in a family with the novel mutation IVS10-1G>A.

In this study, we report a novel deletion mutation of the CCM2 gene in a Chinese patient with multiple CCMs, along with the clinical and neuroradiological features.

CLINICAL PRESENTATION

The patient is a 68-year-old Chinese woman who had a complaint of a 2-week vertigo with tinnitus and denied any headache, vomiting, diplopia, dysarthria, weakness or numbness in her limbs. She had intermittent vertigo for 4 years, hypertension for 4 years with untreated high blood pressure 160/100 mmHg, and hyperlipidemia for 2 years with statin treatment. The patient had lower extremity deep venous thrombosis 4 years ago with anticoagulation therapy for 1 month at that time. Before she came to our hospital, she had taken an aspirin anti-platelet therapy to prevent cerebral infarction for 2 months but stopped it half a month ago due to gastrointestinal discomfort. The physical examination found nothing abnormal but the right Babinski sign was suspiciously positive. However, when the patient underwent a head computed tomography (CT) scan and magnetic resonance imaging (MRI), cerebral hemorrhage and multiple cerebral microbleeds (CMBs) were found in her brain.

As shown in Figure 1, the lesions are located on the brainstem, cerebellum, temporal lobe, and parietal lobe. The patient had an acute hemorrhage on the lesion of the cerebellum, which may have caused her complaint of vertigo.

Digital subtraction angiography (DSA) found that the patient’s right vertebral artery is posterior inferior cerebellar artery (PICA) type, without any vascular malformation. This examination ruled out other causes of hemorrhage, such as vascular malformation or aneurysm. Mini-Mental State Examination (MMSE) was normal with a score of 27. As to the treatment, we advised the patient to stay in bed and gave her Betahistine to relieve vertigo.

The patient had a family history of cerebral hemorrhage (Figure 2). She had two brothers and three sisters. The older brother (II 1) had a cerebral hemorrhage at 78 years old, with the symptoms of vertigo and nausea. There were multiple CMBs in the SWI of his head MRI. The younger brother (II 5) had a cerebral hemorrhage at 66 years old and his main symptom was also vertigo. Neither of them had hypertension. The proband has a daughter (48 years old now) and a son (43 years old now), and neither of them had cerebral hemorrhage. However, except for the proband, other family members denied the gene detection test.

LABORATORY INVESTIGATIONS AND DIAGNOSTIC TESTS

Materials and Methods

Genomic DNA was extracted from whole blood of the subject using commercial kits and then stored at −20°C. Target acquisition technology was used to capture and enrich all the exons of the disease-related genes (CCM1, CCM2, and CCM3, included in a panel), including their upstream and downstream regions (~25 bp), and then they were sequenced on a high-throughput sequencer (Illumina). The DNA sequences were analyzed by Burrows-Wheeler Aligner (BWA) software. Single nucleotide polymorphisms (SNPs) and insertion-deletions (INDELs) were detected by Genome Analysis Tool Kit (GATK) software. The variants were confirmed by Sanger sequencing, and INDELs were analyzed by a deep algorithm based on the capture area. The variants were considered novel when they were not reported in previous publications or in the following public databases: (1) The Human Gene Mutation Database (HGMD) (http://www.hgmd.org/); (2) Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org/); (3) National Center for Biotechnology Information (NCBI) dbSNP (http://www.ncbi.nlm.nih.gov/snp/); (4) ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/); and (5) 1000 Genomes Project (http://www.internationalgenome.org/). The mutation was predicted by MutationTaster (http://www.mutationtaster.org/).

Gene Analysis

Sequencing in patient II7 (Figure 2) revealed a novel variant in heterozygous condition, c.755delC (NM_031443.3 was selected as the reference sequence). The novel deletion (c.755delC) in the gene CCM2 exon 7 was a frameshift mutation that caused a premature stop codon at the 40th amino acid downstream of the frameshift site (p.S252fs*40X), leading to a truncated MGC4607 protein that resulted in the loss of almost the entire C terminal domain (Figure 3). This variant has not been reported in previous publications or in the public databases mentioned above. CCM1 and CCM3 mutations were not found in the patient.

The mutation c.755delC is predicted to be disease-causing with a probability score of 1, which represents a high “security” of the prediction, by MutationTaster (http://www.mutationtaster.org/). Alignment of CCM2 protein sequences showed that the mutated site is on a very conserved sequence in different mammals, suggesting its importance to CCM2.

DISCUSSION

As discovered by previous studies, three CCM causative genes have been identified: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. The coding proteins constitute a CCM complex that has an important function in endothelial cells and is related to CCM pathogenesis.
FIGURE 1 | (A) Brain CT scan. The white solid arrows show a mixed-density lesion on the left parietal lobe and a high-density lesion on the right cerebellum. (B) T1 and T2 weighted images of the MRI scan. The dotted arrow indicates a popcorn-like mixed signal on T1WI and a high-signal lesion with a hemosiderin deposit surrounded on the T2 weighted image. (C) Susceptibility-weighted imaging (SWI). Black solid arrows indicate the lesions on the parietal lobe, temporal lobe, brainstem and cerebellum.
Gene CCM2 located on chromosome 7 encodes protein malcavernin. This protein is a 444 amino acid protein predicted to contain a phosphotyrosine binding (PTB) domain at its N-terminus (15) and a harmonin-homology domain (HHD) at its C-terminus (15) (Figure 4). CCM2 interacts with CCM1 through the PTB domain via conserved NPxY/F motifs in the KRIT1 N-terminus (17) and directly interacts with the CCM3 C-terminus, where they stabilize each other (18). Therefore, CCM2 plays a bridge-like role in the CCM complex.

Recently Jiang et al. found that the CCM2 isoforms could be classified into two groups based on their alternative promoters and alternative start codon exons. They discovered a unique PTB domain, namely atypical phosphotyrosine binding (aPTB) domain. Both CCM1 and CCM3 can bind competitively to this aPTB domain, suggesting CCM2 as a cornerstone for CCM signaling complex (19).

As reported by previous studies, a majority of mutations in these three genes result in truncations of their protein products, which leads to defective expression (20). As shown in Figure 4, for the newly discovered mutation p.S252fs140X, the truncated protein product lost almost the whole HHD domain due to the premature termination codon.

In 2009, Harel et al. found that the C-terminus of CCM2 was linked to inducing cell death through a pathway involving
the neurotrophin receptor TrkA (21). In 2013, Fisher et al. (16) found that the C-terminus of CCM2 can independently fold as a stable globular domain comprised of a five-helix bundle that they denote as helices H1 to H5 with a 4-residue helix (H1*). They found that there is distinct structural similarity to Usher syndrome scaffolding protein harmonin, a protein involved in mechanotransduction in hair cell bundles (22, 23). Therefore, they called this domain in CCM2 the harmonin-homology domain, or HHD (16). This domain interacts with MAP kinase kinase kinase (MEKK3) by binding to its N-terminus (24). Although disruption of this interaction does not influence MEKK3 catalytic activity, it indeed changes the subcellular localization of MEKK3 and then increases Rho/ROCK signaling (25). Furthermore, the disruption of their interaction increases the permeability of the neurovasculature in vivo (24), which may imply a possible mechanism of CCM with HHD damage.

The mutation p.S252fs*40X leads to the loss of all five helical bundles from H1 (residues 293-307) to H5 (residues 258-372), so we can predict that the abnormal product has a functional deficiency because of the loss of the HHD domain. Considering the function of HHD we mentioned before, it seems reasonable to predict that this mutation is a disease-causing mutation.

To date, more than 74 gene mutations of CCM2 have been reported, including nonsense, frameshift, splice mutations, and copy number variants (CNVs) (26). Approximately 45% are deletion mutations, which is consistent with the previous report published in 2007 but higher than the reported 38% (27). In conclusion, ~13 mutations (17% of total CCM2 mutations) were found in exons 7-10 (28–33), which may impact the HHD. In contrast, almost 83% of mutations were located in exons 1-6, which may have an influence on the PTB domain. In Chinese population, there are about 10 CCM2 variants reported in familial and sporadic cases, 30% are deletion, 20% are missense mutations, 20% are insertion mutations, and others are nonsense mutations, silent mutations and substitutions (1, 6, 34–36). Among them, 30% are located on HHD (1, 6, 35).

The relationship between phenotypes and genotypes should be studied further. Some CCM gene polymorphisms have significant associations with CCM symptomatology (37). Although the initial clinical symptoms are similar among the CCM1, CCM2, and CCM3 mutations, the CCM3 mutations appear to be related to more specific and severe phenotypes and earlier onset ages, while the CCM2 mutation carriers tend to have milder phenotypes (38). This finding may explain the mismatching of the relatively mild symptoms and the c.755delC mutation resulting in the nearly total loss of the HHD in this patient.

Family members of the patient refused to take gene examination, so we cannot provide more information about the penetrance of CCM2. As mentioned above, Scimone et al. found that the penetrance of CCM2 was 70% (14). He stated in the article that there were some carriers of IVS10-1G>A mutation, in age of 29–34, showing neither clinical symptoms nor cerebral cavernous malformations in MRI. One hypothesis
was that they all in a young age compare to the disease's incidence age. But there were two family members with the similar situation, means they had same genotypes and similar age, whereas only one experienced the disease. Hence there may exist other genetic environmental factors that will affect the phenotype of CCM2.

**CONCLUSION**

We report a case of CCM and its associated symptoms and genotypes. The deletion c.755delC is a novel mutation that has not been reported before or found in public databases. It is vital for researchers to determine the relationship between CCM phenotypes and genotypes and discover the role of CCM2 in the CCM complex.

**DATA AVAILABILITY STATEMENT**

Publicly available datasets were analyzed in this study. This data can be found here: http://www.hgmd.org/, http://exac.broadinstitute.org/, http://www.ncbi.nlm.nih.gov/snp/, https://www.ncbi.nlm.nih.gov/clinvar/, http://www.w.internationalgenome.org/.

**REFERENCES**

1. Wang K, Wu D, Zhang B, Zhao G. Novel KRT1/CCM1 and MGC4607/CCM2 gene variants in Chinese families with cerebral cavernous malformations. Front Neurol. (2018) 9:1128. doi: 10.3389/fneur.2018.01128
2. Spiegler S, Rath M, Paperlein C, Felbor U. Cerebral cavernous malformations: an update on prevalence, molecular genetic analyses, and genetic counselling. Mol Syndromol. (2018) 9:60–9. doi: 10.1159/000486292
3. Labauge P, Denier C, Bergametti F, Tournier-Lasserve E. Genetics of cavernous angiomas. Lancet Neurol. (2007) 6:237–44. doi: 10.1016/S1474-4422(07)70053-4
4. Cavalcanti DD, Kalani MY, Martirosyan NL, Eales J, Spetzler RF, Preul MC. Cerebral cavernous malformations: from genes to proteins to disease. J Neurosurg. (2012) 116:122–32. doi: 10.3171/2011.8.JNS11241
5. Haasdijk RA, Cheng C, Maat-Kievit AJ, Duckers HJ. Cerebral cavernous malformations: from molecular pathogenesis to genetic counselling and clinical management. Eur J Hum Genet. (2012) 20:134–40. doi: 10.1038/ejhg.2011.155
6. Chang CW, Hsu PW, Wei KC, Chang CW, Fung HC, Hsih MS, et al. CCM1 and CCM2 variants in patients with cerebral cavernous malformations in an ethnically Chinese population in Taiwan. Sci Rep. (2019) 9:12387. doi: 10.1038/s41598-019-4898-5
7. Batra S, Lin D, Recinos PF, Zhang J, Rigamonti D. Cavernous malformations: natural history, diagnosis and treatment. Nat Rev Neurol. (2009) 5:659–70. doi: 10.1038/nrrenuro.2009.177
8. Kim J. Introduction to cerebral cavernous malformation: a brief review. BMB Rep. (2016) 49:555–62. doi: 10.5483/BMBRep.2016.49.5.036
9. Zabranski JM, Wascher TM, Spetzler RF, Johnson B, Golfinos J, Drayer BP, et al. The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg. (1994) 80:422–32. doi: 10.3171/jns.1994.80.3.0422
10. Craig HD, Gunel M, Cepeda O, Johnson EW, Pateck L, Steinberg GK, et al. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15–13 and 3q25.2–27. Hum Mol Genet. (1998) 7:1851–8. doi: 10.1093/hmg/7.12.1851
11. Gunel M, Awad IA, Anson J, Lifton RP. Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21. Proc Natl Acad Sci USA. (1995) 92:6620–4. doi: 10.1073/pnas.92.14.6620
12. Li X, Fisher OS, Boggon TJ. The cerebral cavernous malformations proteins. Oncotarget. (2015) 6:32279–80. doi: 10.18632/oncotarget.5443
13. de Vos JJ, Vreeburg M, Koek GH, van Steensel MA. Review of familial cerebral cavernous malformations and report of seven additional families. Am J Med Genet A. (2017) 173:338–51. doi: 10.1002/ajmg.a.38028
14. Scimone C, Donato L, Katsarou Z, Bostanjopouloiu S, D’Angelo R, Sidoti A. Two Novel KRT1 and CCM2 mutations in patients affected by cerebral cavernous malformations: new information on CCM2 penetrance. Front Neurol. (2018) 9:953. doi: 10.3389/fneur.2018.00953
15. Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, et al. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet. (2003) 73:1459–64. doi: 10.1086/380314
16. Fisher OS, Zhang R, Li X, Murphy JW, Demeler B, Boggon TJ. Structural studies of cerebral cavernous malformations 2 (CCM2) reveal a folded helical domain at its C-terminus. FEBS Lett. (2013) 587:272–7. doi: 10.1016/j.febslet.2012.12.011
17. Zawistowski JS, Stalheim L, Ullik MT, Abell AN, Ancrile BB, Johnson GL, et al. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet. (2005) 14:2521–31. doi: 10.1093/hmg/ddi256
18. Drahaim KM, Li X, Zhang R, Fisher OS, Villari G, Boggon TJ, et al. CCM2–CCM3 interaction stabilizes their protein expression and permits endothelial network formation. J Cell Biol. (2015) 208:987–1001. doi: 10.1083/jcb.201407129
19. Jiang X, Padarti A, Qiu Y, Sheng S, Abou-Fadel J, Badr A, et al. Alternatively spliced isoforms reveal a novel type of PTB domain in CCM2 protein. Sci Rep. (2019) 9:15808. doi: 10.1038/s41598-019-52386-0
20. Fisher OS, Liu W, Zhang R, Stiegler AL, Ghedia S, Weber JL, et al. Structural basis for the disruption of the cerebral cavernous malformations 2 (CCM2) interaction with Krev interaction trapped 1 (KRIT1) by disease-associated mutations. J Biol Chem. (2015) 290:2842–53. doi: 10.1074/jbc.M114.616433
21. Harel L, Costa B, Tcherpakov M, Zapata M, Oberthuer A, Hansford LM, et al. CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron. (2009) 63:585–91. doi: 10.1016/j.neuron.2009.08.020
22. Yan J, Pan L, Chen X, Wu L, Zhang M. The structure of the harmonin/sans complex reveals an unexpected interaction mode of the two Usher syndrome proteins. Proc Natl Acad Sci USA. (2010) 107:4040–5. doi: 10.1073/pnas.0911385107

**ETHICS STATEMENT**

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

LY designed the study, analyzed the data, and drafted the manuscript. JZ participated in the validation of the new mutation and revised the manuscript. JW participated in the analyses of the data and improved the study design.

**ACKNOWLEDGMENTS**

The authors wish to thank the patient and her family for their contributions to the study.
23. Pan L, Yan J, Wu L, Zhang M. Assembling stable hair cell tip link complex via multidentate interactions between harmonin and cadherin 23. *Proc Natl Acad Sci USA*. (2009) 106:5575–80. doi: 10.1073/pnas.0901819106

24. Fisher OS, Deng H, Liu D, Zhang Y, Wei R, Deng Y, et al. Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex. *Nat Commun.*. (2015) 6:7937. doi: 10.1038/ncomms8937

25. Chohan MO, Marchio S, Morrison LA, Sidman RL, Cavenee WK, Dejana E, et al. Emerging pharmacologic targets in cerebral cavernous malformation and potential strategies to alter the natural history of a difficult disease: a review. *JAMA Neurol.*. (2019) 76:492–500. doi: 10.1001/jamaneurol.2018.83634

26. Much CD, Schwefel K, Skowronek D, Shoubash L, von Podewils F, Elbracht M, et al. Novel pathogenic variants in a cassette exon of CCM2 in patients with cerebral cavernous malformations. *Front Neurol.* (2019) 10:1219. doi: 10.3389/fneur.2019.01219

27. Liquori CL, Berg MJ, Squitieri F, Leedom TP, Ptacek L, Johnson EW, et al. Deletions in CCM2 are a common cause of cerebral cavernous malformations. *Am J Hum Genet.*. (2007) 80:69–75. doi: 10.1086/510439

28. Denier C, Goutagny S, Labauge P, Krivosec V, Arnout M, Cousin A, et al. Mutations within the MGC4607 gene cause cerebral cavernous malformations. *Am J Hum Genet.*. (2004) 74:326–37. doi: 10.1086/381718

29. Riant F, Cecillon M, Saugier-Veber P, Tournier-Lasserve E. CCM molecular screening in a diagnosis context: novel unclassified variants leading to abnormal splicing and importance of large deletions. *Neurogenetics*. (2013) 14:133–41. doi: 10.1007/s10048-013-0362-0

30. D’Angelo R, Alafaci C, Scimone C, Ruggeri A, Salpietro FM, Bramanti P, et al. Sporadic cerebral cavernous malformations: report of further mutations of CCM genes in 40 Italian patients. *Biomed Res Int.* (2013) 2013:459253. doi: 10.1155/2013/459253

31. Mondejar R, Solano F, Rubio R, Delgado M, Perez-Sempere A, Gonzalez-Meneses A, et al. Mutation prevalence of cerebral cavernous malformation genes in Spanish patients. *PLoS ONE*. (2014) 9:e86286. doi: 10.1371/journal.pone.0086286

32. Spiegler S, Najm J, Liu J, Gkalympoudis S, Schroder W, Borck G, et al. High mutation detection ratesin cerebral cavernous malformation upon stringent inclusion criteria: one-third of probands are minors. *Mol Genet Genomic Med.*. (2014) 2:176–85. doi: 10.1002/mgg3.60

33. Nardella G, Visci G, Guarnieri V, Castellana S, Biagini T, Bisceglia L, et al. A single-center study on 140 patients with cerebral cavernous malformations: 28 new pathogenic variants and functional characterization of a PDCD10 large deletion. *Hum Mutat.*. (2018) 39:1885–900. doi: 10.1002/humu.23629

34. Du Q, Shi Z, Chen H, Zhang Y, Wang J, Zhou H. Two novel CCM2 heterozygous mutations associated with cerebral cavernous malformation in a chinese family. *J Mol Neurosci.*. (2019) 67:467–71. doi: 10.1007/s12031-018-1254-4

35. Huang WQ, Lu CX, Zhang Y, Yi KH, Cai LL, Li ML, et al. A novel CCM2 gene mutation associated with familial cerebral cavernous malformation. *Front Aging Neurosci.*. (2016) 8:220. doi: 10.3389/fnagi.2016.00220

36. Jih KY, Chung CP, Chang YN, Hung PL, Soong BW, Liao YC, et al. Mutational analysis of CCM1, CCM2 and CCM3 in a Han Chinese cohort with multiple cerebral cavernous malformations in Taiwan. *Clin Genet.*. (2018) 94:389–90. doi: 10.1111/cge.13377

37. Rinaldi C, Bramanti P, Scimone C, Donato L, Alafaci C, D’Angelo R, et al. Relevance of CCM gene polymorphisms for clinical management of sporadic cerebral cavernous malformations. *J Neurol Sci.*. (2017) 380:31–7. doi: 10.1016/j.jns.2017.06.043

38. Denier C, Labauge P, Bergametti F, Marchelli F, Riant F, Arnout M, et al. Genotype-phenotype correlations in cerebral cavernous malformations. *Ann Neurol.*. (2006) 60:550–6. doi: 10.1002/ana.20947

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yang, Wu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.